Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review

Aspirin appeared as a medicine to deal with aches and inflammation, but due to its antiplatelet properties, it has evolved into a drug mainly used to avert cardiovascular disease. Regardless of its therapeutic uses, the limiting aspect for aspirin use has been its affiliation with gastrointestinal (...

Full description

Saved in:
Bibliographic Details
Published in:International journal of general medicine 2021-08, Vol.14, p.4757-4763
Main Authors: Kedir, Hanan Muzeyin, Sisay, Eskinder Ayalew, Abiye, Alfoalem Araba
Format: Article
Language:English
Subjects:
Aspirin
Cardiovascular disease
Cardiovascular diseases
Clinical trials
Complications and side effects
Drug dosages
enteric coated
gastrointestinal
Gastrointestinal diseases
Omeprazole
Review
side effects
Systematic review
Ulcers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aspirin appeared as a medicine to deal with aches and inflammation, but due to its antiplatelet properties, it has evolved into a drug mainly used to avert cardiovascular disease. Regardless of its therapeutic uses, the limiting aspect for aspirin use has been its affiliation with gastrointestinal (GI) toxicity, classifying from acute mucosal damage to GI problems and death. The aim of this systematic review is to address the question regarding the ECA effect on the gastric mucosa. A systematic search of the literature was conducted in the PubMed electronic databases from April 10th to April 23rd, 2020. Eligibility has been set, and based on those criteria, initially a total of 637 results were obtained, from these 58 of them were not written in English. Then, 168 articles which were free from duplication were screened and all the included articles were RCTs published after 2000. Based on these, final number of articles included on this review was 6. Data were obtained from 6 published articles which reported on 15,621 participants. The reports were from 3 different countries. Most of the studies revealed that enteric-coated aspirin (ECA) treatment was not an effective mechanism against GI protection. ECA administration with omeprazole can hugely reduce the incidence of endoscopic GI damage compared to the impact of ECA used alone. Even short-term administration of a low dose of ECA was significantly associated with an apparent small bowel injury. ECA treatment is not an effective mechanism against GI protection, and it is highly associated with small bowel injury. So the coating does not reduce risk of GI complications.
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S326929